Adverse events3,321

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 3,321

Type	Event	Organ system	Group	Affected	At risk	Events
other	Atrioventricular block first degree	Cardiac disorders	Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCC	1	2	1
other	Atrioventricular block first degree	Cardiac disorders	Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLC	0	1	0
other	Atrioventricular block first degree	Cardiac disorders	Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: EC	0	124	0
other	Atrioventricular block first degree	Cardiac disorders	Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCC	0	145	0
other	Atrioventricular block first degree	Cardiac disorders	Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: Melanoma	0	21	0
other	Atrioventricular block first degree	Cardiac disorders	Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLC	0	21	0
other	Atrioventricular block first degree	Cardiac disorders	Phase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCC	0	22	0
other	Atrioventricular block first degree	Cardiac disorders	Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UC	0	20	0
other	Atrioventricular block first degree	Cardiac disorders	Phase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma	0	1	0
other	Ventricular arrhythmia	Cardiac disorders	Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCC	1	2	1
other	Ventricular arrhythmia	Cardiac disorders	Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLC	0	1	0
other	Ventricular arrhythmia	Cardiac disorders	Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: EC	0	124	0
other	Ventricular arrhythmia	Cardiac disorders	Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCC	0	145	0
other	Ventricular arrhythmia	Cardiac disorders	Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: Melanoma	0	21	0
other	Ventricular arrhythmia	Cardiac disorders	Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLC	0	21	0
other	Ventricular arrhythmia	Cardiac disorders	Phase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCC	0	22	0
other	Ventricular arrhythmia	Cardiac disorders	Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UC	0	20	0
other	Ventricular arrhythmia	Cardiac disorders	Phase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma	0	1	0
other	Hypothyroidism	Endocrine disorders	Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCC	1	2	1
other	Hypothyroidism	Endocrine disorders	Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLC	1	1	1

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02501096/events

API reference For AI assistants

Adverse events3,321

Sources 3

Read this list from software.